← Browse by Condition
Medical Condition
prostatic neoplasms castration resistant
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 4, Phase 1, Phase 2, Phase 2
ClinicalMetric tracks all active clinical trials for prostatic neoplasms castration resistant sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — prostatic neoplasms castration resistant Clinical Trials
How many clinical trials are currently recruiting for prostatic neoplasms castration resistant?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for prostatic neoplasms castration resistant, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for prostatic neoplasms castration resistant?
prostatic neoplasms castration resistant research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a prostatic neoplasms castration resistant clinical trial?
Eligibility criteria for prostatic neoplasms castration resistant trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 2
Phase 4 1
Top Sponsors
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06706921 Phase 4
Recruiting
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Enrollment
15 pts
Location
United States
Sponsor
VA Greater Los Angeles Healthc...
NCT04868604 Phase 1, Phase 2
Recruiting
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Enrollment
54 pts
Location
United States
Sponsor
Clarity Pharmaceuticals Ltd
NCT05393791 Phase 2
Recruiting
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Enrollment
168 pts
Location
Australia, Netherlan...
Sponsor
Leiden University Medical Cent...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology